2-(TERT-butyl)-4-methylphenyl appended 1,4-diazepane based novel TFEB activating compounds as autophagy modulators for neurodegenerative disorders including alzheimer's disease (AD)
2-(TERT-butyl)-4-methylphenyl appended 1,4-diazepane compounds activate TFEB to enhance autophagy, addressing the barrier crossing challenge and effectively clearing Tau aggregates and neurofibrillary tangles in neurodegenerative disorders like Alzheimer's disease.
Patent Information
- Application Number
- PCT/US2025/024325
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-12
- Filing Date
- 2025-04-11
- Publication Date
- 2025-10-16
AI Technical Summary
Current treatments for neurodegenerative disorders like Alzheimer's disease, particularly those targeting Tau aggregates and neurofibrillary tangles, face challenges in crossing the blood-brain barrier and effectively promoting their clearance, with no effective Tau-targeting therapies available.
Development of 2-(TERT-butyl)-4-methylphenyl appended 1,4-diazepane compounds that act as TFEB activators, enhancing autophagy to clear Tau aggregates and neurofibrillary tangles by modulating autophagic pathways, including compounds of Formula (I) and (II), and their pharmaceutical compositions.
These compounds effectively cross the blood-brain barrier and enhance autophagic clearance of Tau aggregates and neurofibrillary tangles, providing a potential therapeutic approach for neurodegenerative disorders.